Journals / The Anatolian Journal of Cardiology / 2018 / Cilt: 19 - Sayı: 4

Fulminant myocarditis: Characteristics, treatment, and outcomes

Pages
279–286
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Finally, the outcome of FM was critically revised according to the current published registries focusing on thetopic.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Myocarditis is an inflammatory disease of the myocardium with a broad spectrum of clinical presentations, ranging from mild symptoms to severeheart failure.
📊
Key Findings & Data:The course of patients with myocarditis is heterogeneous, varying from partial or full clinical recovery in few days to advancedlow cardiac output syndrome requiring mechanical circulatory support or heart transplantation.
💡
Conclusion & Impact:Finally, the outcome of FM was critically revised according to the current published registries focusing on thetopic.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Myocarditis is an inflammatory disease of the myocardium with a broad spectrum of clinical presentations, ranging from mild symptoms to severeheart failure. The course of patients with myocarditis is heterogeneous, varying from partial or full clinical recovery in few days to advancedlow cardiac output syndrome requiring mechanical circulatory support or heart transplantation. Fulminant myocarditis (FM) is a peculiar clinicalcondition and is an acute form of myocarditis, whose main characteristic is a rapidly progressive clinical course with the need for hemodynamicsupport. Despite the common medical belief of the past decades, recent comprehensive data, including a recent registry that compared FM withacute non-FM, highlighted that FM has a poor inhospital outcome, often requires advanced hemodynamic support, and may result in residualleft ventricular dysfunction in survivors. This review aimed to provide an updated practical definition of FM, including essentials in the diagnosisand management of the disease. Finally, the outcome of FM was critically revised according to the current published registries focusing on thetopic.

🔖

Cite This Article

VERONESE, G., AMMİRATİ, E., CİPRİANİ, M., FRİGERİO, M. (2018). Fulminant myocarditis: Characteristics, treatment, and outcomes. The Anatolian Journal of Cardiology, Cilt: 19 - Sayı: 4, 279–286. https://ajindex.com/articles/365808

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Anzini M, Merlo M, Sabbadini G, Barbati G, Finocchiaro G, Pinamonti B, et al. Long-term evolution and prognostic stratification of biopsy-proven active myocarditis. Circulation 2013; 128: 2384-94.
  2. Matsuura H, Ichida F, Saji T, Ogawa S, Waki K, Kaneko M, et al. Clinical Features of Acute and Fulminant Myocarditis in Children- 2nd Nationwide Survey by Japanese Society of Pediatric Cardiology and Cardiac Surgery. Circ J 2016; 80: 2362-8. [CrossRef] Teele SA, Allan CK, Laussen PC, Newburger JW, Gauvreau K, Thiagarajan RR. Management and outcomes in pediatric patients presenting with acute fulminant myocarditis. J Pediatr 2011; 158: 638-43. [CrossRef] Amabile N, Fraisse A, Bouvenot J, Chetaille P, Ovaert C. Outcome of acute fulminant myocarditis in children. Heart 2006; 92: 1269-73.
  3. Heymans S, Eriksson U, Lehtonen J, Cooper LT Jr. The Quest for New Approaches in Myocarditis and Inflammatory Cardiomyopathy. J Am Coll Cardiol 2016; 68: 2348-64. [CrossRef] Blauwet LA, Cooper LT. Idiopathic giant cell myocarditis and cardiac sarcoidosis. Heart Fail Rev 2013; 18: 733-46. [CrossRef] Ammirati E, Stucchi M, Brambatti M, Spano F, Bonacina E, Recalcati F, et al. Eosinophilic myocarditis: a paraneoplastic event. Lancet. 2015; 385: 2546. [CrossRef] Ammirati E, Oliva F, Belli O, Bonacina E, Pedrotti P, Turazza FM, et al. Giant cell myocarditis successfully treated with antithymocyte globuline and extracorporeal membrane oxygenation for 21 days. J Cardiovasc Med (Hagerstown) 2016; 17 (Suppl 2): e151-3. [CrossRef] Cooper LT Jr, Hare JM, Tazelaar HD, Edwards WD, Starling RC, Deng MC, et al. Usefulness of immunosuppression for giant cell myocarditis. Am J Cardiol 2008; 102: 1535-9. [CrossRef] Brambatti M, Matassini MV, Adler ED, Klingel K, Camici PG, Ammirati E. Eosinophilic Myocarditis: Characteristics, Treatment, and Outcomes. J Am Coll Cardiol. 2017; 70: 2363-75. [CrossRef] Frustaci A, Chimenti C. Immunosuppressive therapy in myocarditis. Circ J 2015; 79: 4-7. [CrossRef] Schultheiss HP, Kuhl U, Cooper LT. The management of myocarditis. Eur Heart J 2011; 32: 2616-25. [CrossRef] Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al; Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Associati